

# SESSION DETAILS

# Life Sciences Summit 2011

*SHOWCASING INNOVATION, PROMOTING COLLABORATION*

8:15 AM –9:40 AM, WHARTON BALLROOM

**WELCOMING REMARKS AND OPENING PLENARY SESSION**

**The Power of Patients: Their Role in Developing New Translational Research Models to Accelerate the Quest for Cures**

A *Newsweek* article entitled “Desperately Seeking Cures” (May 14, 2010) reported that from “1996 to 1999, the US food and Drug Administration approved 157 new drugs....from 2006 to 2009—the agency approved 74.” This article further mentioned that not among them were any therapies for diseases such as Alzheimer’s, lung or pancreatic cancer, Parkinson’s, or Huntington’s. This information is disheartening but not surprising for patients afflicted with these and a myriad of other diseases for which there are no effective treatments despite the talents and efforts of hundreds of thousands researchers and drug developers worldwide. The panelists will share their views on therapeutic productivity from the perspective of those who have the greatest stake in the outcome - patients. What can be done today and in five and ten years to establish and support models that will deliver on the promise faster?

*Moderator:*

- Thomas A. Picone, PhD, Principal, Partners Unlimited

*Panelists:*

- Deborah W. Brooks, Co-Founder and Executive Vice Chairman, The Michael J. Fox Foundation for Parkinson's Research
- Louis J. DeGennaro, PhD, Chief Mission Officer, Executive Vice President, Leukemia and Lymphoma Society
- Howard Fillit, MD, Executive Director, Alzheimer's Drug Discovery Foundation
- Robert Ring, PhD, Vice President, Translational Research, Autism Speaks
- George Vradenburg, President, Vradenburg Foundation

Biographies of speakers follow this section.

9:45 AM–10:55 AM, SOHO ROOM

### **TRANSLATIONAL RESEARCH FORUM**

#### **Infectious Diseases Key Opinion Leader Session**

The emergence of a plethora of clinically useful antibacterial agents in the 20th century has sometimes been thought to mark an end to the need for additional new antibiotics, as the mortality burden associated with microbial disease has definitely been alleviated to a considerable extent. However, the resiliency of bacteria to environmental pressures, including xenobiotics such as antibacterial agents, suggests that the situation is more dynamic than it appears on the surface. Indeed, the continued development of bacterial resistance to available antibacterial agents strongly suggests that there will be an ongoing need for the discovery and development of new antibiotics. A number of potential solutions have been advanced. This session will focus on some of the more exciting recent small and large molecule developments in the antibacterial agent field. The wide variety of potential therapeutic and prophylactic approaches under investigation suggests that this session will be a vibrant one, with a strong interplay between representatives from both the academic and industrial sectors.

*Moderator:*

- Michael Barbachyn, PhD, Head of External Science, AstraZeneca

*Panelists:*

- Juliane Bubeck-Wardenburg, MD, PhD, Assistant Professor, Microbiology, Pediatrics, University of Chicago
- Arturo Casadevall, MD, PhD, Professor & Chair, Microbiology & Immunology, Albert Einstein College of Medicine
- Alan Cross, MD, Professor, Medicine, University of Maryland School of Medicine
- Vance Fowler, MD, MHS, Associate Professor, Medicine, Division of Infectious Diseases, Duke University

9:45 AM–10:55 AM, TRIBECA ROOM

**TRANSLATIONAL RESEARCH FORUM**

**Regenerative Medicine Key Opinion Leader Session**

The promise of regenerative medicine is the restoration of structure, function and self-healing capacity to damaged or diseased tissues. The history of regenerative medicine notably includes bone marrow transplantation, living skin equivalents, autologous cartilage repair from cultured cells, and growth factors for spinal fusion. The future may include treatments for major diseases of the cardiovascular, neurological, hepatic, pulmonary and renal systems. The basic principles of regeneration are preservation of space, and the provision of cells, nutrients, matrix and signaling molecules. Successful cell therapies and the engineering of functional human tissues and organs suitable for surgical implantation will require advances in methods for innervation and vascularization to ensure complete integration and long-term viability. Organ printing and decellularized matrices are two technologies that have the potential to address these issues. Presentations in this track will discuss recent developments in bioengineering technology and the main challenges for future practical applications in regenerative medicine.

*Moderator:*

- Sudha Kadiyala, PhD, Senior Director, Business Development & Strategic Planning, Advanced Technologies & Regenerative Medicine, LLC (ATRM), Johnson & Johnson

*Panelists:*

- Arnold Caplan, PhD, Professor, Biology, Professor, General Medical Sciences (Oncology), Case Western University
- Sheng Ding, PhD, Senior Investigator and Professor, Gladstone Institute of Cardiovascular Disease, Department of Pharmaceutical Chemistry, University of California San Francisco
- Alan J. Russell, PhD, Founding Director, McGowan Institute for Regenerative Medicine
- Gordana Vunjak-Novakovic, PhD, Professor, Biomedical Engineering, Columbia University

## Wednesday, November 16, 2011

---

Biographies of speakers follow this section.

11:15 AM–12:10 PM, SOHO ROOM

### TRANSLATIONAL RESEARCH PRESENTATION

#### Infectious Diseases 1

This session will feature presentations from academic scientists working in breakthrough areas of commercial relevance. Descriptions of each presenter's research can be found below.

*Moderator:*

- Timothy J. Pelura, PhD, Chairman, President & CEO, Immunome Inc.

*Panelists:*

- Arturo Casadevall, MD, PhD, Professor & Chair, Microbiology & Immunology, Albert Einstein College of Medicine
  - *Dr. Casadevall works on the mechanisms of antibody-mediated immunity. He is an advocate of the re-introduction of antibody-based therapies in infectious disease*
- James Collins, PhD, Professor, Biomedical Engineering, Boston University, Founding member, Wyss Institute for Biologically Inspired Engineering, Harvard University
  - *Professor Collins' group works in synthetic biology and systems biology with a particular focus on network biology approaches to antibiotic action and bacterial defense mechanisms.*
- Lizbeth Hedstrom, PhD, Professor, Biology, Brandeis University
  - *The Hedstrom laboratory investigates the biochemistry of proteases and enzymes in the nucleotide biosynthetic pathways.*
- Barry N. Kreiswirth, PhD, Professor, Director, TB Center, Public Health Research Institute, University of Medicine & Dentistry of New Jersey
  - *The genetic characterization of multidrug resistant bacterial pathogens.*

---

11:15 AM–12:10 PM, TRIBECA ROOM

### BUSINESS WORKSHOP

#### Beyond VCs and Wall Street: The Role of Government Agencies and Foundation as Fuel to the Life Science R&D Engine

Today the financial world supporting life science research and development efforts is at a standstill. On the one hand the VC model has proven incapable of supporting the needs of the market and industry alone and on the other big pharma's and the public market as well as angel investor have not proven themselves capable of stepping in and covering the gap. To many this is spelled "Valley of Death". Non-diluting funding represent a possible alternative and a definite complementary source of funding aimed at supporting R&D and possibly could assist the industry to lay a bridge over the valley.

*Moderator:*

- Ram May-Ron, Managing Partner, FreeMind Group

*Panelists:*

- Jonathan J. Fleming, Managing General Partner, Oxford Bioscience Partners
- Michael G. Kurilla, MD, PhD, Director, BioDefense Research Affairs, Associate Director, BioDefense Product Development, DMID, NIAID, NIH, DHHS
- Sharon E. Semones, Portfolio Consultant, Global External Research and Development, Eli Lilly & Company
- Lance Stewart, PhD, Chief Executive Officer, Emerald BioStructures
- Barry Wolitzky, PhD, Executive Director of Strategic Partnering, Immune Tolerance Network

---

12:15 PM–1:10 PM, WHARTON BALLROOM & ATRIUM

**OPEN LUNCH**

---

1:15 PM–2:10 PM, SOHO ROOM

**TRANSLATIONAL RESEARCH PRESENTATION**

**Regenerative Medicine 1**

This session will feature presentations from academic scientists working in breakthrough areas of commercial relevance. Descriptions of each presenter's research can be found below.

*Moderator:*

- Sridevi Dhanaraj, PhD, Group Manager, Advanced Technologies and Regenerative Medicine, LLC (ATRM), Johnson & Johnson

*Panelists:*

- Arnold Caplan, PhD, Professor, Biology, Professor, General Medical Sciences (Oncology), Case Western University
  - *The emphasis of our studies is to develop and refine the technology necessary to isolate one of these rare stem cells, the mesenchymal stem cell (MSC).*
- Hans-Willem Snoeck, MD, PhD, Associate Professor, Oncological Sciences, Medicine, Infectious Diseases, Mount Sinai School of Medicine
  - *Hematopoietic and human pluripotent stem cell biology.*
- Gordana Vunjak-Novakovic, PhD, Professor, Biomedical Engineering, Columbia University
  - *My laboratory works on engineering of functional human tissues for application in regenerative medicine, study of disease and stem cell research.*
- Michael Young, PhD, Associate Scientist & de Gunzburg Director, Minda de Gunzburg Research Center for Ocular Regeneration, Schepens Eye Research Institute, Associate Professor, Ophthalmology, Harvard Medical School
  - *My work involves developing novel therapies for blinding diseases through the use of stem cells and tissue engineering.*

---

1:30 PM–2:40 PM, TRIBECA ROOM

**BUSINESS WORKSHOP**

**Reimbursement: Why Is It Important To Think About Getting Paid Early?**

This workshop will address the health care payment environment and why management of emerging companies should think about reimbursement even at the earliest stages of development. A thoughtful plan to address this critical issue will position an emerging company attract investors as well as partners.

*Moderator:*

- Anna D. Kraus, Of Counsel, Covington & Burling LLP

*Panelists:*

- Les Funtleyder, Health Care Strategist & Portfolio Manager, Miller Tabak Health Care Transformation Fund, Miller Tabak + Co., LLC
- Kent Rogers, MBA, Vice President, Managed Markets, Acorda Therapeutics
- Lambert van der Walde, Founder, van der Walde & Co.

## Wednesday, November 16, 2011

---

Biographies of speakers follow this section.

2:15 PM–3:10 PM, SOHO ROOM

### TRANSLATIONAL RESEARCH PRESENTATION

#### Infectious Diseases 2

This session will feature presentations from academic scientists working in breakthrough areas of commercial relevance. Descriptions of each presenter's research can be found below.

*Moderator:*

- Leah Lipsich, PhD, Executive Director, Immunology & Inflammation, Regeneron

*Panelists:*

- Juliane Bubeck-Wardenburg, MD, PhD, Assistant Professor, Microbiology, Pediatrics, University of Chicago
  - *Investigation of the host-pathogen interaction in Staphylococcus aureus disease, defining essential pathogenic strategies that can be targeted through novel vaccine and small molecule-based approaches.*
- Peder S. Olofsson, MD, PhD, Institute Scientist, The Feinstein Institute for Medical Research
  - *Mechanisms for nervous control of immune cell activity.*
- Alexander Ploss, PhD, Assistant Professor, The Rockefeller University
  - *Dr. Ploss uses humanized mouse technology to study human infectious diseases in vivo.*
- Daniel Wozniak, PhD, Professor, Infectious Diseases, Ohio State University
  - *Polysaccharides and biofilms of pathogenic bacteria.*

---

2:15 PM–3:10 PM, TRIBECA ROOM

### BUSINESS WORKSHOP

#### Financing Mechanisms for Emerging Companies: Venture Capital, Debt Financing, Angel Investments, Royalty Monetizations, and Other Alternative Financing Structures.

This panel will discuss practical tools and mechanisms for financing an academic start-up company. While the environment is difficult, there are many financing alternatives to support emerging companies. Emerging companies should assess a number of options to raise capital to best match their financing needs.

*Moderator:*

- Luke C. Düster, Principal, Capital Royalty L.P

*Panelists:*

- Louis Berneman, Founding Partner, Osage University Partners
- Michael J. Hanewich, Head of Life Sciences East, Life Science Venture Capital, Silicon Valley Bank
- Kristen C. Kosofsky, Managing Director, Horizon Technology Finance
- Barry Myers, MD, PhD, MBA, Executive-in-Residence, Pappas Ventures
- Evonne Sepsis, Managing Director, ECS Advisors

---

3:15 PM–4:10 PM, SOHO ROOM

## TRANSLATIONAL RESEARCH PRESENTATION

### Regenerative Medicine 2

This session will feature presentations from academic scientists working in breakthrough areas of commercial relevance. Descriptions of each presenter's research can be found below.

Moderator:

- Brock Reeve, MPhil, MBA, Executive Director, Harvard Stem Cell Institute

Panelists:

- Scott Banta, PhD, Associate Professor, Chemical Engineering, Columbia University
  - *My research is focused in applied protein and metabolic engineering with applications in gene and drug delivery, protein and peptide conformational behavior, biomolecular recognition, biosensors, bioelectrocatalysis and biomaterials.*
- Emilia Entcheva, PhD, Associate Professor, Biomedical Engineering, Physiology and Biophysics, Stony Brook University
  - *Dr. Entcheva's lab does pioneering work in the new area of cardiac optogenetics, combining it with state-of-the-art imaging technology.*
- Daniel A. Grande, PhD, Associate Investigator, Director of Orthopaedic Research, Feinstein Institute for Medical Research
  - *Orthopaedic surgical devices and regenerative medicine strategies for repair of the musculoskeletal system*
- Mark Noble, PhD, Professor, Biomedical Genetics, Neurobiology and Anatomy, Neurology, University of Rochester
  - *Replacing astrocytes, the major support cell of the central nervous system, is dramatically improving our ability to repair damage to the brain and spinal cord.*

---

3:15 PM–4:10 PM, TRIBECA ROOM

## BUSINESS WORKSHOP

### Proof of Relevance: What is it and Why is This Concept a Critical Consideration for Emerging Companies

In order to attract partners and investors, management of emerging biotech companies have to move beyond a focus on achievement of Proof of Concept to one of Proof of Relevance - that is, the ability to recognize and communicate the indisputable clinical and commercial value of compounds at early stages of development. Ed Saltzman will focus on the importance of seeking Proof of Relevance for early-stage programs and provide recent examples of strategies for achieving value inflection from demonstration of Proof of Relevance in early-stage development.

Presenter:

- Ed Saltzman, President, Defined Health

Biographies of speakers follow this section.

4:15 PM–5:30 PM, WHARTON BALLROOM

### **PLENARY SESSION**

#### **Working Together: The Need is Mutual**

In recent years, new industry-academic partnerships have started to emerge that align the depth of academic discovery and innovation with the expertise drug developers. Many of these partnerships are characterized by new paradigms that address issues that used to get in the way of deeper and more productive collaborations on the part of academic investigators and their institutions and the biopharmaceutical industry. These new models have the potential to make therapeutic development more efficient and productive, benefitting all stakeholders including patients. This panel will discuss these new models, what makes them unique and lessons that have been learned as they venture into new territory.

*Moderator:*

- Charles A. Weiss, Partner, Kenyon & Kenyon LLP

*Panelists:*

- Karen Bernstein, PhD, Co-Founder & Chairman, BioCentury Publications
- David Berry, MD, PhD, Partner, Flagship Ventures
- Ronald Newbold, PhD, Vice President, Strategic Research Partnerships, External R&D Innovations, Pfizer Inc
- Greg Wiederrecht, PhD, Vice President, Worldwide Licensing & External Research, Merck

8:15 AM–9:40 AM, WHARTON BALLROOM

**OPENING PLENARY SESSION**

**Evolution or Revolution? Transforming How Basic Research Discoveries Become Life Saving Therapies**

The inefficiency of bringing new biomedical discoveries to market has been an issue of international debate. Despite an NIH budget of \$31B and increased investment by the pharmaceutical industry in research and development, the number of drug approvals has not improved in decades, and the gap between academic discovery and commercialization continues to widen. A confluence of issues including the pharmaceutical industries need to fill its pipeline, the crushing demands on our healthcare system to address the needs of an aging and growing population, and decreasing support for our basic research enterprise has set the stage for change. Will our system simply evolve, or could something more “revolutionary” be in the making? Our panelists will debate the needs, opportunities, challenges and priorities we face as we seek to transform how basic research discoveries become life-saving therapies.

*Introduction:*

- Amanda Cashin, PhD, Vice President, Life Sciences, Alexandria Real Estate Equities, Inc.

*Moderator:*

- Maria Freire, PhD, President, Albert and Mary Lasker Foundation

*Panelists:*

- James H. Sabry, MD, Vice President, Genentech Partnering, Genentech Inc
- George Scangos, PhD, Chief Executive Officer, Biogen Idec
- Bruce Stillman, PhD, President, Cold Spring Harbor Laboratory
- Marc Tessier-Lavigne, PhD, President and Professor, Laboratory of Brain Development and Repair, The Rockefeller University

Biographies of speakers follow this section.

9:45 AM–10:55 AM, SOHO ROOM

### TRANSLATIONAL RESEARCH FORUM

#### Oncology Key Opinion Leader Session

The availability of many novel and meaningful drugs that have been approved over the past fifteen years has created a blockbuster market that has made oncology a major Biopharma focus as evidenced by the large percentage of drugs in the pipeline and the significant number and size of oncology deals. Interestingly, only in oncology do we see significant deals occurring prior to the advent of substantive human clinical data. In areas outside of cancer where unmet needs are often considered less significant, similar high-value deals have traditionally required Proof of Concept data, and more recently, Proof of Relevance (PoR) data has become the emerging standard; that is, targeting a clear unmet need and powering for a convincing benefit over an available standard of care.

For pre-revenue stage companies, the implications of these issues are critical for partnering, for example: how much focus the large players are putting on biomarkers and diagnostics (e.g., Novartis' acquisition of Genoptix); what is the appetite for cytotoxics and reformulated chemotherapeutics in the face of generics (e.g., Lilly's recent venture investment in Cerulean); and, are the large players broadening their horizons to more complicated therapeutic modalities with the approval and launch of Provenge (as perhaps exemplified by the Amgen-Biovex deal on OncoVex?).

*Moderator:*

- Andrew Dorner, PhD, Vice President, Millennium Pharmaceuticals

*Panelists:*

- Robert L. Comis, MD, Professor & Director, Drexel University Clinical Trials Research Center
- Louis J. DeGennaro, PhD, Chief Mission Officer, Executive Vice President, Leukemia and Lymphoma Society
- Eric K. Rowinsky, MD, Adjunct Professor, New York University
- Howard Scher, MD, Chief, Genitourinary Oncology Service, Sidney Kimmel Center for Urologic and Prostate Cancers, Memorial Sloan-Kettering Cancer Center

9:45 AM–10:55 AM, TRIBECA ROOM

**TRANSLATIONAL RESEARCH FORUM**

**Neurology Key Opinion Leader Session**

Neurodegenerative disorders affect an estimated 10 million people globally each year, a figure that is expected to grow by approximately 20% over the next decade as human life span and the aging-population continue to increase. Research continues to validate the important biological relationship between neurodegenerative and neurobehavioral disabilities and understanding the critical genetic, molecular and anatomical connections between the two may ultimately allow for more synergistic and effective treatments.

The opening session will explore emerging challenges and opportunities in the fields of neurodegenerative diseases and associated neurobehavioral disorders. Key Opinion Leaders will provide a broad perspective on the state of the science and its potential to impact the development of new therapies and improved patient care. While genetic underpinnings of these disorders remain a focal point for ongoing research and therapeutic development, scientists are also exploring the underlying role of environmental influences in precipitating the onset of disease, and the potential to intervene in this progression. How these dynamics affect the course of therapeutic development for neurological disorders, and which scientific advances represent real opportunities for therapeutic development will be debated. Follow-on sessions will feature academic scientists working in breakthrough areas of neurodegenerative and neurobehavioral disorders.

*Moderator:*

- Anthony Caggiano, MD, PhD, Vice President, Preclinical Development, Acorda Therapeutics

*Panelists:*

- Fritz Henn, PhD, MD, Professor, Neuroscience, Cold Spring Harbor Laboratory
- Lauren B. Krupp, MD, Professor of Neurology and Psychology, Director, National Pediatric MS Center, co-director, MS Comprehensive Care Center, Director, Neuropsychology Research, Stony Brook University Medical Center
- Warren J. Strittmatter, MD, Chief, Division of Neurology, Duke Medical Center
- Zhenyu Yue, PhD, Associate Professor, Department of Neurology & Neuroscience, Mount Sinai School of Medicine

## Thursday, November 17, 2011

---

Biographies of speakers follow this section.

11:15 AM–12:10 PM, SOHO ROOM

### TRANSLATIONAL RESEARCH PRESENTATION

#### Oncology 1

This session will feature presentations from academic scientists working in breakthrough areas of commercial relevance. Descriptions of each presenter's research can be found below.

*Moderator:*

- Joseph Brindisi, Business Development Advisor, Prism BioLabs Corporation

*Panelists:*

- Anne R. Bresnick, PhD, Professor, Biochemistry, Albert Einstein College of Medicine
  - *Molecular mechanisms regulating myosin-II organization during normal cell physiology as well as the pathologies contributing to tumor cell invasion and metastasis.*
- Michael Kalos, PhD, Adjunct Associate Professor, Pathology and Laboratory Medicine, Director, Translational and Correlative Studies Laboratory, University of Pennsylvania
  - *Focused on the development of novel approaches and methodologies to enhance patient immunity against cancer and evaluating the impact of experimental treatments on patient biology.*
- Mark Noble, PhD, Professor, Biomedical Genetics, Neurobiology and Anatomy, Neurology, University of Rochester
  - *Selective targeting of cancer stem cells promises a revolution in our ability to treat multiple types of malignancies.*
- Mark R. Philips, MD, Professor of Medicine, Cell Biology & Pharmacology, NYU School of Medicine, Associate Director for Basic Science, NYU Cancer Institute, Director, MST (MD/PhD) Program
  - *The Philips lab studies the post-translational modification and subcellular trafficking of Ras oncoproteins and is actively involved in developing anti-Ras drugs that block this pathway.*

---

11:15 AM–12:10 PM, TRIBECA ROOM

### BUSINESS WORKSHOP

#### Technology Transfer: Evolving to Meet The Needs of Multiple Stakeholders

The practice of technology transfer, in particular with regard to drug development, is evolving to meet the needs of numerous stakeholders. Academic institutions that rely on the income stream to replace declining grant revenue; patients waiting for therapies; biopharmaceutical companies seeking to enhance pipelines; investors looking for new opportunities; and, researchers with discoveries that have the potential to help patients. By necessity, the practice of technology transfer has to evolve to meet the needs of all stakeholders. This panel will the future of moving academic discoveries into the hands of drug developers and considerations for all stakeholders.

*Moderator:*

- Barbara A. Sawitsky, MBA, CLP, Director of Patents & Licensing & Business Development, The New York Blood Center and the Lindsley F. Kimball Research Institute (LFKRI)

*Panelists:*

- Kathleen A. Denis, PhD, CLP, Associate Vice President, Office of Technology Transfer, The Rockefeller University
- E. Jonathan Soderstrom, PhD, Managing Director, Office of Cooperative Research, Yale University
- Gunther Winkler, PhD, Board of Trustees, Beth Israel Deaconess Medical Center and member of the Research Oversight Committee

---

12:15 PM–1:10 PM, WHARTON BALLROOM & ATRIUM

## OPEN LUNCH

---

1:15 PM–2:10 PM, SOHO ROOM

## TRANSLATIONAL RESEARCH PRESENTATION

### Neurology 1

This session will feature presentations from academic scientists working in breakthrough areas of commercial relevance. Descriptions of each presenter's research can be found below.

*Moderator:*

- Joan Fallon, DC, MSc, Chief Executive Officer, Curemark

*Panelists:*

- Ottavio Arancio, MD, PhD, Associate Professor, Pathology & Cell Biology, Columbia University Medical Center
  - *Dr. Arancio's laboratory has focused primarily on events triggered by amyloid protein.*
- Joel Bergman, PhD, Post Doc, University of Illinois at Chicago
  - *My research focuses on using medicinal chemistry to answer specific questions of biological significance, more specifically to develop small molecules as chemical tools and therapeutics.*
- Gareth John, PhD, Associate Professor, Mount Sinai School of Medicine
  - *Dr. John's research focuses on the design of novel neuroprotective therapies for conditions including multiple sclerosis, stroke, traumatic CNS injury.*
- Murali Ramanathan, PhD, Professor, Pharmaceutical Sciences, Neurology, State University of New York at Buffalo
  - *Dr. Ramanathan's research interests are in multiple sclerosis therapeutics and pharmacogenomic modeling.*

---

1:15 PM–2:10 PM, TRIBECA ROOM

## BUSINESS WORKSHOP

### Drug Development Basics: It is a Very Multidisciplinary Effort

Taking an asset from early discovery through to commercial development is a very complicated process, requiring many steps that satisfy not only regulatory requirements but commercial reality. A thorough understanding of this process will help entrepreneurial investigators and emerging management teams attract development partners and funding. This panel will provide top-line guidance on the issues and considerations.

*Moderator:*

- Jules T. Mitchel, PhD, President, Target Health Inc.

*Panelists:*

- Afia K. Asamoah, former Special Assistant to the Principal Deputy Commissioner, FDA, Senior Associate, Covington & Burling LLP
- Braham Shroot, PhD, Chief Executive Officer, Argyle Therapeutics Inc.
- Barbara S. Slusher, PhD, MBA, Chief Scientific Officer, Brain Science Institute, NeuroTranslational Program, Johns Hopkins School of Medicine
- A. Donny Strosberg, PhD, Professor, The Scripps Research Institute-Florida
- Charles P. Theuer, MD, PhD, President & CEO, Tracon Pharma

## Thursday, November 17, 2011

---

Biographies of speakers follow this section.

2:15 PM–3:10 PM, SOHO ROOM

### TRANSLATIONAL RESEARCH PRESENTATION

#### Oncology 2

This session will feature presentations from academic scientists working in breakthrough areas of commercial relevance. Descriptions of each presenter's research can be found below.

*Moderator:*

- Andrew Dorner, PhD, Vice President, Millennium Pharmaceuticals

*Panelists:*

- Renier J. Brentjens, MD, PhD, Medical Oncologist, Memorial Sloan-Kettering Cancer Center
  - *Patient T cells modified ex vivo to express artificial receptors specific to tumor antigens for subsequent infusion back into patients to induce an anti-tumor response.*
- Jian Cao, PhD, Assistant Professor, Medicine & Pathology, Stony Brook University
  - *The Cao lab is interested in understanding the mechanism of cancer invasion/metastasis and developing inhibitors targeting this disseminated process.*
- Gunda Georg, PhD, Professor and Head, Department of Medicinal Chemistry, Director, Institute for Therapeutics Discovery & Development, University of Minnesota
  - *The design, synthesis, and preclinical in vivo antitumor and toxicity evaluation of Minnelide, a highly water-soluble and effective prodrug of triptolide will be discussed.*
- Hermann Steller, PhD, Strang Professor, Investigator, Howard Hughes Medical Institute, Strang Laboratory of Apoptosis and Cancer Biology, The Rockefeller University
  - *Investigating the mechanism by which cells undergo apoptosis, how this process is regulated by distinct signaling pathways, and how abnormal regulation contributes to a variety of diseases.*

---

2:15 PM–3:10 PM, TRIBECA ROOM

### BUSINESS WORKSHOP

#### Intellectual Property: Rethinking Value, Rethinking the Way it's Been Done, Changing the Paradigm

There is pressure on established and emerging industry and academia to find new and more efficient ways to collaborate to benefit from the advancement and commercialization therapeutics. It is understood that solid IP protection is a must to attract any investor or collaborator while valuation is often an issue that interferes with efficient translation. This panel will discuss the issues of IP as they relate to academic-industry collaboration and the transitions in thinking about it and its value that are emerging on both sides of the deal.

*Moderator:*

- Anthony Giaccio, Partner, Kenyon & Kenyon LLP

*Panelists:*

- Richard A. Basile, Chief Executive Officer and Principal, BioPontis Alliance LLC
- Eric Cottingham, PhD, Vice President for Research and Technology Management, Memorial Sloan-Kettering Cancer Center
- Thomas Gallagher, Chief Patent Counsel, Kadmon Corporation, LLC
- Charles Ryan, PhD, JD, Senior Vice President & Chief Intellectual Property Counsel, Forest Laboratories, Inc.

---

3:15 PM–4:10 PM, SOHO ROOM

## TRANSLATIONAL RESEARCH PRESENTATION

### Neurology 2

This session will feature presentations from academic scientists working in breakthrough areas of commercial relevance. Descriptions of each presenter's research can be found below.

*Moderator:*

- Min Cho, PhD, Associate Editor, Nature Neuroscience

*Panelists:*

- P. Jeffrey Conn, PhD, Lee E. Limbird Professor of Pharmacology, Director, Vanderbilt Center for Neuroscience Drug Discovery
  - *Research in my lab is focused on the discovery of molecular probes and drug candidates that may provide novel therapeutic approaches for CNS disorders.*
- Jian Feng, PhD, Professor, Physiology and Biophysics, State University of New York at Buffalo
  - *Dr. Feng's research is focused on discovering novel Parkinson's disease drugs using midbrain dopaminergic neurons derived from patient-specific iPSC cells.*
- Fritz Henn, PhD, MD, Professor, Neuroscience, Cold Spring Harbor Laboratory
  - *Uncovered a new component of the circuit mediating depression, a viable target for Deep Brain stimulation in intractable cases, providing clues for developing more effective medications.*
- William E. Van Nostrand, PhD, Professor, Medicine, Stony Brook University
  - *Dr. Van Nostrand's research interests are in studying novel amyloid peptide – protein interactions in the CNS and neurodegenerative diseases.*

---

3:15 PM–4:10 PM, TRIBECA ROOM

## BUSINESS WORKSHOP

### Working with the Biopharmaceutical Industry: They Want to Work With You

Arguably, the best organizations to collaborate with to advance the development of a novel therapeutic are those organizations that have done it many times before - the pharmaceutical companies. However, approaching a pharma can appear daunting to a CEO of an emerging company. This panel will elucidate the ins and outs of approaching a pharma including understanding their strategy and how you can demonstrate that you fit that strategy and expectations on both sides.

*Moderator:*

- James Foley, PhD, Managing Director, Aqua Partners LLC

*Panelists:*

- Katherine E. Breedis, CFA, CMT, Senior Director, Global External Research & Development, Eli Lilly & Company
- Susan Rohrer, PhD, Senior Director, External Scientific Affairs, Merck
- Christopher Yochim, Director, Strategic Planning & Business Development, AstraZeneca
- Robert A. Zivin, PhD, Senior Director, Corporate Office of Science & Technology, Johnson & Johnson

Biographies of speakers follow this section.

4:15 PM–5:30 PM, WHARTON BALLROOM

**CLOSING PLENARY SESSION**

**Funding Innovative New Medicines: Where is the Money?**

The development of new therapeutics has many stakeholders: academic institutions that rely on revenue streams and furthering knowledge; biopharmaceutical companies that need to fill or expand their pipelines; investors that look for a return on the risk they take; patients who suffer from diseases for which there are no treatments; and, finally, friends and family of patients whose targeted philanthropic contributions support medical research. Even with the unending need for new therapeutics, the funding environment for life sciences has gotten more and more difficult for many reasons. Yet, despite that difficulty, a number of projects and companies are getting funded. This panel will discuss the characteristics of fundable projects and companies and share their views on what will be fundable in the future.

*Moderator:*

- Ellen B. Coreswet, Partner, Covington & Burling LLP

*Panelists:*

- Colin Goddard, PhD, Executive Chairman & Acting CEO, Coferon, Inc.
- Jennifer Friel Goldstein, BSE, MB, MBA, Director, Venture Capital, Pfizer Inc.
- Shaun Grady, Vice President, Strategic Partnering and Corporate Business Development, AstraZeneca
- Joanna Horobin, President & CEO, Syndax Pharmaceuticals
- Scott M. Napolitano, Managing Director, Peter J. Solomon Company
- Cary G. Pfeffer, MD, Partner, Third Rock Ventures